About The Study: In this randomized clinical trial, clesrovimab, a long-acting monoclonal antibody, was well tolerated in infants at increased risk for severe respiratory syncytial virus (RSV) disease through 2 RSV seasons. These findings support the use of clesrovimab in children who remain at risk for severe RSV disease in their second RSV season.
Corresponding Author: To contact the corresponding author, Anushua Sinha, MD, MPH, email anushua.sinha@merck.com.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamapediatrics.2026.2760)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2026.2760?guestAccessKey=c016cf02-707b-4125-8157-fc7f04a8e4c5&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=072026
Journal
JAMA Pediatrics